Akari Therapeutics, Plc (AKTX) Debt Components
- 2026-03-31: Short-term DebtUSD (m); Notes Payable, CurrentUSD $49.00K; Short-term Debt, Percentage Bearing Fixed Interest Ratepure (m); Debt Instrument, Convertible, Conversion PriceUSD/shares (m).
- 2025-12-31: Short-term DebtUSD (m); Notes Payable, CurrentUSD $81.00K; Short-term Debt, Percentage Bearing Fixed Interest Ratepure (m); Debt Instrument, Convertible, Conversion PriceUSD/shares (m).
- 2025-09-30: Short-term DebtUSD (m); Notes Payable, CurrentUSD $198.00K; Short-term Debt, Percentage Bearing Fixed Interest Ratepure (m); Debt Instrument, Convertible, Conversion PriceUSD/shares (m).
- 2025-06-30: Short-term DebtUSD (m); Notes Payable, CurrentUSD $179.00K; Short-term Debt, Percentage Bearing Fixed Interest Ratepure (m); Debt Instrument, Convertible, Conversion PriceUSD/shares (m).
Akari Therapeutics, Plc Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Short-term Debt USD | Notes Payable, Current USD | Short-term Debt, Percentage Bearing Fixed Interest Rate pure | Debt Instrument, Convertible, Conversion Price USD/shares | Convertible Notes Payable, Current USD | Debt Instrument, Face Amount USD | Debt Instrument, Interest Rate, Stated Percentage pure | Debt Instrument, Convertible, Beneficial Conversion Feature USD | Debt Instrument, Increase, Accrued Interest USD | Debt Instrument, Unamortized Discount USD | Debt Instrument Issued Principal USD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | (m) | $49.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $81.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $198.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $179.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $228.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $659.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-10-31 | (m) | (m) | (m) | 1.59 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $200.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $600.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $900.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-02-29 | $1.10M | (m) | 7.49% | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-04-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $26.83K | (m) | $448.94K |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $1.20K | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | 5.00% | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | 10.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-08-31 | (m) | (m) | (m) | (m) | (m) | (m) | 1.00% | (m) | (m) | (m) | (m) |
| 2021-05-31 | (m) | (m) | (m) | (m) | (m) | (m) | 1.00% | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.00M | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.00M | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $250.00K | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | $898.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | $1.10M | (m) | (m) | (m) | $202.00K | (m) |
| 2012-04-04 | (m) | (m) | (m) | 1.71 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-04-04 | (m) | (m) | (m) | (m) | (m) | $1.10M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |